Data from the British Society for Rheumatology Biologics Register, a national prospective observational cohort study of biological safety in patients with rheumatoid arthritis (RA), compared the incidence of VTE between 11,881 anti-TNF-α- (IFX, adalimumab, and etanercept) and 3673 nonbiological disease-modifying antirheumatic drug (nbDMARD)-treated patients [28]. The gene discussed is TNF; the disease is rheumatoid arthritis.